PennyStockPayCheck.com Rss

Featured Posts

Chase Bank Limits Cash Withdrawals, Bans International... Before you read this report, remember to sign up to http://pennystockpaycheck.com for 100% free stock alerts Chase Bank has moved to limit cash withdrawals while banning business customers from sending...

Read more

Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...

Read more

Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday

Read more

Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...

Read more

UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...

Read more

Amarin Prescription Fish-Oil Pill Approved

Category : Stocks

Updated with new information.

BEDMINSTER, NJ (TheStreet) –The U.S. Food and Drug Administration on Thursday approved a prescription fish-oil pill from Amarin that will be used to treat patients with very high levels of triglycerides, a type of fat found in blood.

Amarin’s newly approved drug Vascepa is made from ultra-purified ethyl EPA, an omega-3 fatty acid commonly found in fish. An FDA spokesperson confirmed the approval. …

Click to view a price quote on AMRN.

Click to research the Drugs industry.

More here: Amarin Prescription Fish-Oil Pill Approved

Post to Twitter

Sparking gains in Irish biotech firm Amarin ([[AMRN]] +8.6%) is a Leerink Swann note speculating that "patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101."…

Category : Stocks, World News

Sparking gains in Irish biotech firm Amarin (AMRN +8.6%) is a Leerink Swann note speculating that “patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101.” The firm had earlier said AMRN was moving toward winning its quest for U.S. patent protection for AMR-101. Post your comment!

View post: Sparking gains in Irish biotech firm Amarin ([[AMRN]] +8.6%) is a Leerink Swann note speculating that "patent progress could solidify Amarin as a prime takeout candidate given the blockbuster potential for [heart-drug candidate] AMR-101."…

Post to Twitter